Jefferies analyst Michael Yee initiated coverage of Blueprint Medicines (BPMC) with a Buy rating and $135 price target The firm finds the stock “quite attractive,” especially on the recent pullback. The shares should rebound higher this year as Blueprint executes on the Ayvakit launch and beats numbers and raises guidance, the analyst tells investors in a research note. Jefferies thinks momentum for the launch will continue with growing numbers of diagnosed patients and increased utilization driven by greater physician and patient awareness.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Blueprint Medicines initiated with an Outperform at Scotiabank
- Blueprint Medicines: Hold Rating Amid Concerns Over Ayvakit’s Liver Function Test Elevations
- Cautious Optimism: Hold Rating Given to Blueprint Medicines Amid Financial Performance Concerns and Slower Ayvakit Growth Projections
- Blueprint Medicines price target raised to $135 from $127 at Baird
Questions or Comments about the article? Write to editor@tipranks.com